Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 3
1980 1
1987 1
1990 1
1993 1
1994 2
1995 1
1996 6
1997 10
1998 6
1999 26
2000 37
2001 63
2002 78
2003 127
2004 174
2005 226
2006 249
2007 309
2008 334
2009 368
2010 462
2011 493
2012 512
2013 567
2014 497
2015 568
2016 532
2017 527
2018 484
2019 232
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

6,064 results
Results by year
Filters applied: . Clear all
Page 1
Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T, et al. Int J Mol Sci 2017 - Review. PMID 28671573 Free PMC article.
Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). ...Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. ...
Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance betwee …
Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y, et al. Curr Top Med Chem 2018 - Review. PMID 30526462
Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. ...
Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of H
Histone deacetylase inhibitors: a review on class-I specific inhibition.
Behera J, et al. Mini Rev Med Chem 2015 - Review. PMID 25994050
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. ...Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer....
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to presen
Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC, et al. J Cancer Res Ther 2014 - Review. PMID 25313724 Free article.
The enzymes Histone Acetyl Transferase (HAT) and Histone Deacetylase (HDAC) control the level of acetylation of histones and thereby alter gene expression. ...Histone Deacetylase Inhibitors (HDACI) exert anticancer activity by promoting acetylation of histones as well as by promoting acetylation of non-histone protein substrates. ...
The enzymes Histone Acetyl Transferase (HAT) and Histone Deacetylase (HDAC) control the level of acetylation of histone …
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S, et al. Eur J Med Chem 2019 - Review. PMID 30594678
The histone deacetylases (HDACs) enzymes provided crucial role in transcriptional regulation of cells through deacetylation of nuclear histone proteins. ...The pan-HDAC inhibitors can confront these conditions but have chances to affect epigenetic functions of other HDAC isoforms. ...
The histone deacetylases (HDACs) enzymes provided crucial role in transcriptional regulation of cells through deacetylation of …
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT, et al. Expert Opin Ther Pat 2017 - Review. PMID 28033734
FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activtiy has been implicated in a variety of human diseases, such as cancers, virus infection, and neurodegenerative diseases. ...Areas covered: This review covers new patents and articles about isoform- or class-selective HDAC inhibitors during the last four years, as well as the therapeutic potential of these compounds. ...
FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase
Pharmacogenomics and histone deacetylase inhibitors.
Goey AK, et al. Pharmacogenomics 2016 - Review. PMID 27767376 Free PMC article.
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents. ...
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more rec …
Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
Melesina J, et al. Future Med Chem 2018. PMID 29966452
For two decades, a classical pharmacophore model comprising a zinc binding group, a linker and a cap group, has been used for the development of histone deacetylase (HDAC) inhibitors. ...We, therefore, propose an extended pharmacophore model, which can describe almost all currently known HDAC inhibitors. This pharmacophore consists of six pharmacophoric features and should be helpful for the classification and design of selective HDAC inhibitors....
For two decades, a classical pharmacophore model comprising a zinc binding group, a linker and a cap group, has been used for the developmen …
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
Minucci S and Pelicci PG. Nat Rev Cancer 2006 - Review. PMID 16397526 Free article.
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. ...
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and
Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.
Zhou N, et al. Drug Discov Ther 2015 - Review. PMID 26193935 Free article.
Histone deacetylases (HDACs) are a family of metal enzymes which mainly regulates the acetylation level of histone, together with histone acetyl transferases (HATs). ...This brief review will mainly talk about several reported chimeric HDACs-PTKs inhibitors....
Histone deacetylases (HDACs) are a family of metal enzymes which mainly regulates the acetylation level of histone, tog
6,064 results
Jump to page
Feedback